SONN Sonnet BioTherapeutic
- 2.5700
- -0.0600-2.28%
- 2.5500
- -0.0200-0.78%
Sonnet BioTherapeutic News
Sonnet BioTherapeutics Releases Virtual Investor '"What This Means" Segment
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
Gold Down Over 2%; CVS Health Shares Jump After Q3 Results
12 Health Care Stocks Moving In Wednesday's Intraday Session
Trending Stocks Today | FOXO Technologies Surges 172.81%
Express News | Sonnet BioTherapeutics Shares Resume Trade
Express News | Sonnet BioTherapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 106.9%
Sonnet BioTherapeutics Announces Issuance Of U.S. Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates
Express News | Sonnet Biotherapeutics Holdings Inc - Patent Term Effective Until June 2044
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates
Express News | Sonnet Biotherapeutics Announces Issuance of U.S. Patent Covering a Variant Il-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates
Top Midday Decliners
Sonnet Stock Tumbles 22% in Wake of Proposed Offering Filing
Dow Jumps Over 300 Points; ON Semiconductor Earnings Top Views
Sonnet Biotherapeutics Files To Sell Common Stock, Warrants; Terms Not Disclosed
12 Health Care Stocks Moving In Thursday's Intraday Session
Sonnet BioTherapeutics Inc. Regains Compliance With Nasdaq
Express News | Sonnet Biotherapeutics Inc. Regains Compliance With Nasdaq
Express News | Sonnet BioTherapeutics Shares Are Trading Higher After the Company Announced That It Has Entered Into a Licensing Agreement With Alkem Laboratories for the Research, Development, Manufacturing, Marketing and Commercialization of Its Molecule SON-080...
Express News | Sonnet Biotherapeutics Holdings Inc - Entitled to Receive Low Double-Digit Royalty on Net Sales of Son-080
Analysis
Price Target
No Data
No Data